Lazaar AL - Search Results

1

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial.

Lazaar AL, Miller BE, Donald AC, Keeley T, Ambery C, Russell J, Watz H, Tal-Singer R; for 205724 Investigators. Lazaar AL, et al. Respir Res. 2020 Jun 12;21(1):149. doi: 10.1186/s12931-020-01401-4. Respir Res. 2020. PMID: 32532258 Free PMC article. Clinical Trial.

2

Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.

Lazaar AL, Miller BE, Tabberer M, Yonchuk J, Leidy N, Ambery C, Bloomer J, Watz H, Tal-Singer R. Lazaar AL, et al. Eur Respir J. 2018 Oct 4;52(4):1801020. doi: 10.1183/13993003.01020-2018. Print 2018 Oct. Eur Respir J. 2018. PMID: 30139779 Free article. Clinical Trial. No abstract available.

3

SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.

Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R. Lazaar AL, et al. Br J Clin Pharmacol. 2011 Aug;72(2):282-93. doi: 10.1111/j.1365-2125.2011.03968.x. Br J Clin Pharmacol. 2011. PMID: 21426372 Free PMC article. Clinical Trial.

4

Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.

Watz H, Mistry SJ, Lazaar AL; IPC101939 investigators. Watz H, et al. Among authors: lazaar al. Pulm Pharmacol Ther. 2013 Oct;26(5):588-95. doi: 10.1016/j.pupt.2013.05.004. Epub 2013 May 21. Pulm Pharmacol Ther. 2013. PMID: 23701917 Clinical Trial.

5

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.

Miller BE, Mistry S, Smart K, Connolly P, Carpenter DC, Cooray H, Bloomer JC, Tal-Singer R, Lazaar AL. Miller BE, et al. Among authors: lazaar al. BMC Pharmacol Toxicol. 2015 Jun 20;16:18. doi: 10.1186/s40360-015-0017-x. BMC Pharmacol Toxicol. 2015. PMID: 26092545 Free PMC article. Clinical Trial.

6

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Danirixin Hydrobromide Tablets in Japanese Healthy Elderly Participants.

Iida T, Matsuzawa Y, Ogura H, Nagakubo T, Wakamatsu A, Ambery C, Miller BE, Lazaar AL, Numachi Y. Iida T, et al. Among authors: lazaar al. Clin Pharmacol Drug Dev. 2019 Nov;8(8):1081-1087. doi: 10.1002/cpdd.693. Epub 2019 May 6. Clin Pharmacol Drug Dev. 2019. PMID: 31056840 Clinical Trial.

7

Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort.

Stott-Miller M, Müllerová H, Miller B, Tabberer M, El Baou C, Keeley T, Martinez FJ, Han M, Dransfield M, Hansel NN, Cooper CB, Woodruff P, Ortega VE, Comellas AP, Paine Iii R, Kanner RE, Anderson W, Drummond MB, Kim V, Tal-Singer R, Lazaar AL. Stott-Miller M, et al. Among authors: lazaar al. Int J Chron Obstruct Pulmon Dis. 2020 Oct 13;15:2467-2476. doi: 10.2147/COPD.S267002. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33116463 Free PMC article.

8

CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin.

Keir HR, Richardson H, Fillmore C, Shoemark A, Lazaar AL, Miller BE, Tal-Singer R, Chalmers JD, Mohan D. Keir HR, et al. Among authors: lazaar al. ERJ Open Res. 2020 Nov 10;6(4):00583-2020. doi: 10.1183/23120541.00583-2020. eCollection 2020 Oct. ERJ Open Res. 2020. PMID: 33263062 Free PMC article.

9

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.

Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL; CF2110399 Investigators. Moss RB, et al. Among authors: lazaar al. J Cyst Fibros. 2013 May;12(3):241-8. doi: 10.1016/j.jcf.2012.08.016. Epub 2012 Sep 17. J Cyst Fibros. 2013. PMID: 22995323 Free article. Clinical Trial.

10

Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations.

Bloomer JC, Ambery C, Miller BE, Connolly P, Garden H, Henley N, Hodnett N, Keel S, Kreindler JL, Lloyd RS, Matthews W, Yonchuk J, Lazaar AL. Bloomer JC, et al. Among authors: lazaar al. Eur J Pharm Biopharm. 2017 Aug;117:224-231. doi: 10.1016/j.ejpb.2017.03.023. Epub 2017 Apr 3. Eur J Pharm Biopharm. 2017. PMID: 28385615 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page